# A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

> **NCT04646590** · PHASE3 · UNKNOWN · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 28904 (actual)

## Conditions studied

- Prevention of COVID-19
- Safety and Efficacy

## Interventions

- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cell) group
- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cells) placebo group

## Key facts

- **NCT ID:** NCT04646590
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-16
- **Primary completion:** 2021-11-28
- **Final completion:** 2022-12
- **Target enrollment:** 28904 (ACTUAL)
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04646590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04646590, "A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04646590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*